On April 17, 2023 ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases, reported it will present new, preclinical data showing that its lead asset, ZB131, directed against cancer-specific plectin (CSP), represents a promising approach for antibody-drug conjugates (ADCs) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 (Press release, ZielBio, APR 17, 2023, View Source [SID1234630203]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) Annual Meeting is taking place April 14-19, 2023 in Orlando and virtually. ZielBio’s Dr. Lindsey Brinton, Principal Scientist and Head of Research, and Dr. Samantha Perez, Senior Scientist, will present the data in a poster session on Wednesday, April 19 from 9:00 am to 12:30 pm in Section 21 of the poster hall.
Major advances in payload and linker technology are increasing the clinical adoption of ADCs, leaving an unmet need for the identification of new targets that differentiate cancer cells from healthy cells across multiple tumor types. ZielBio has validated CSP, a pro-tumorigenic protein expressed on the surface of cancer cells, as a high-value drug target and developed ZB131 as a first-in-class anti-CSP monoclonal antibody. ZB131 is currently being evaluated in a Phase 1/2 clinical trial (NCT05074472) across multiple solid tumors.
Research presented at AACR (Free AACR Whitepaper) will focus on CSP as a target for ADCs, demonstrating its abundance on the surface of cancer cells (and not healthy tissue), its bioavailability in humans, and its application across multiple cancer indications. ZB131 demonstrates favorable pharmacokinetics, is rapidly internalized by CSP-expressing tumor cells in mouse models, and can be conjugated to multiple cytotoxic payloads.
"These findings underscore our enthusiasm for CSP as a therapeutic target and ZB131 as an excellent candidate for conjugation to payloads," said Alan Bash, CEO of ZielBio. "We are excited to share this data with the AACR (Free AACR Whitepaper) community and are committed to exploring new avenues for deploying ZB131 against difficult-to-treat cancers."